Statins for multiple sclerosis (Q24234119)

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Therapeutic potential of lovastatin in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Potential of statins for the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Systematic review of the empirical evidence of study publication bias and outcome reporting bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Publication bias in clinical trials due to statistical significance or direction of trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008386.PUB3

Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials

21 January 2018

1 reference

12 December 2020

Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin

1 reference

12 December 2020

High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis

1 reference

12 December 2020

Statins for multiple sclerosis

1 reference

12 December 2020

Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis

1 reference

12 December 2020